EC Number   |
Activating Compound |
Reference |
|---|
   1.1.1.146 | 5-aminoimidazole-4-carboxamide ribonucleoside |
treatment augments the induction of enzyme expression and activity by C2 ceramide |
686411 |
| 1.1.1.146 | bacterial sphingomyelinase |
- |
686411 |
| 1.1.1.146 | C2 ceramide |
treatment of 3T3-L1 preadipocytes robustly induces the expression of isoform 11beta-HSD1 via induction of CCAAT/enhancer-binding protein beta and its binding to the 11beta-HSD1 promoter |
686411 |
| 1.1.1.146 | D-glucose 6-phosphate |
stimulates isoform 11beta-HSD1 reductase activity in liver but not in testis |
741248 |
| 1.1.1.146 | dehydroandrostenedione |
activates isozyme 11beta-HSD1 3fold |
669504 |
| 1.1.1.146 | dexamethasone |
after application of dexamethasone, 11beta-HSD1 mRNA increases in muscle of both diabetic and control subjects, whereas 11beta-HSD2 mRNA decreases. 11beta-HSD1 activity increases in diabetic subjects, but not in controls, whereas 11beta-HSD2 activity does not change in either group |
687961 |
| 1.1.1.146 | glucose |
coexpression with hexose-6-phosphate dehydrogenase potentiates 11beta-HSD1 reductase activity at high glucose, this effect is significantly decreased at low glucose, with concomitantly increased 11beta-HSD1 dehydrogenase activity |
700180 |
| 1.1.1.146 | Insulin |
insulin stimulates 11beta-HSD1 activity and expression in a time- and concentration-dependent manner, the p38 MAPK inhibitor SB-220025, but not the ERK inhibitor U-0126 or the phosphatidylinositol 3-kinase inhibitor LY294002, prevent insulin stimulation of 11beta-HSD1 activity |
697625 |
| 1.1.1.146 | more |
11beta-HSD2mRNA expression increases 2.5fold on day 3 after injection of trehalose-6,6'-dimycolate |
700441 |
| 1.1.1.146 | more |
interleukin-1beta or tissue necrosis factor-alpha simultaneously increase 11beta-HSD1 expression and down-regulate 11beta-HSD2 |
700178 |
